Coherus BioSciences (CHRS) Narrows Q4 Loss
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.46 -1.35%
Revenue Growth %: +91.8%
Financial Fact:
Other income: 348K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +91.8%
Financial Fact:
Other income: 348K
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.47), versus ($3.68) reported last year. Revenue for the quarter came in at $6.5 million, versus $1.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Worthington Industries (WOR) Misses Q4 EPS by 9c
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
